Researchers at Dana-Farber Cancer Institute Inc., Memorial Hospital for Cancer and Allied Diseases, Memorial Sloan Kettering Cancer Center and Stevens Institute of Technology have divulged proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase-binding moiety linked to cyclin-dependent kinase 4 (CDK4) and/or 6 (CDK6)-targeting moiety through a linker.
Nutshell Biotech (Shanghai) Co. Ltd. has identified fused ring compounds acting as fibroblast growth factor receptor 4 (FGFR4) inhibitors reported to be useful for the treatment of cancer and myeloproliferative diseases.
Medshine Discovery Inc. has synthesized PROTAC compounds comprising an E3 ubiquitin ligase binding moiety coupled to IRAK-4-targeting moiety through a linker.
Shanghai Haihe Biopharma Co. Ltd. has disclosed hydroxamic acid compounds acting as ENPP1 inhibitors reported to be useful for the treatment of cancer and infections.
Eli Lilly and Co. has described aryl hydrocarbon receptor (AhR) agonists reported to be useful for the treatment of psoriasis, ulcerative colitis, Crohn’s disease, graft-vs.-host disease and multiple sclerosis.
Medshine Discovery Inc. has divulged halogen-substituted pyridazinone compounds acting as short transient receptor potential channel 5 (TRPC5) antagonists reported to be useful for the treatment of hypertensive nephropathy.
Shanghai Institutes for Biological Sciences and Shanghaitech University have identified dopamine D2 receptor and/or 5-HT receptor agonists reported to be useful for the treatment of depression and schizophrenia.
Black Diamond Therapeutics Inc. has synthesized quinoline derivatives acting as Raf kinase B (B-Raf) mutant inhibitors reported to be useful for the treatment of cancer.
Gilead Sciences Inc. has divulged thienopyrrole compounds acting as Toll-like receptor 7 (TLR7) and/or TLR8 antagonists reported to be useful for the treatment of systemic lupus erythematosus, cutaneous lupus erythematosus, lupus nephritis and inflammatory disorders, among others.
RSS